Core Insights - Dongyangguang Pharmaceutical (600673) has seen a stock increase of nearly 6%, currently up 5.41% at HKD 48.28, with a trading volume of HKD 20.129 million [1] Group 1: Clinical Developments - The National Medical Products Administration has approved Dongyangguang Pharmaceutical's self-developed first-class new drug, HECN30227, for clinical trials aimed at treating chronic hepatitis B, marking a significant advancement in the field of small nucleic acid drug development in China [1] - This development offers new hope for functional cure of hepatitis B [1] Group 2: Market Position and Product Launch - Dongyangguang Pharmaceutical's recently approved product, Fingo Mod (Fingolimod) capsules, is the first generic oral medication for multiple sclerosis (MS) in China, with a global market performance exceeding USD 3.3 billion in 2018 and projected to surpass USD 500 million in 2024 [1] - The project was initiated in 2011, with the company being the first to apply for generic approval in China in 2020, breaking the original research monopoly [1] - Currently, only Dr. Reddy's Laboratories in India has products related to this drug under review [1]

Core Viewpoint - Dongyang Sunshine Pharmaceutical (06887) has seen a nearly 6% increase in stock price following the approval of its self-developed siRNA therapy HECN30227 for clinical trials in chronic hepatitis B treatment, marking a significant advancement in the field of small nucleic acid drug development in China [1] Company Developments - Dongyang Sunshine Pharmaceutical's stock rose by 5.41%, reaching HKD 48.28, with a trading volume of HKD 20.129 million [1] - The approval of HECN30227 offers new hope for functional cure of hepatitis B and signifies a key step in China's small nucleic acid drug research [1] - The company has also recently received approval for its oral drug, FingoMod (Fingolimod hydrochloride capsules), for the treatment of multiple sclerosis (MS), which is the first generic version in China [1] Market Performance - FingoMod has shown strong global market performance, with sales exceeding USD 3.3 billion in 2018 and projected to surpass USD 500 million in 2024 [1] - Dongyang Sunshine Pharmaceutical initiated the FingoMod project in 2011 and has filed for approval in multiple countries, with the first generic application submitted in China in 2020 [1] - Currently, only Dr. Reddy's Laboratories in India has products related to FingoMod under review [1]